-
Schools closed as Indonesia battles wildfires
-
Wallabies lock Amatosero given three-match ban for Japan red card
-
Swiatek dominates Shnaider to set up Toronto semi with Svitolina
-
Swiatek races into Toronto semis as Svitolina battles through
-
Oil prices rise further as hopes for Hormuz deal fade
-
'Big Four' bowlers back as ageing Australia begin gruelling run
-
One year after Putin-Trump summit, 'spirit of Anchorage' dissipated
-
AI's hunger for power sparks US private gas plant boom
-
Farage vs Count Binface: What to know about UK snap poll
-
Memphis AI data center fuels pollution fight in Black neighborhood
-
Torment of Afghan fathers as daughters deprived of education
-
Ceuta leader wants migrant detention centre after influx
-
Return of displaced Syrian Kurds to hometown suspended after violence
-
Colombia scrambles to find survivors as quake kills 111
-
Swiatek races past Shnaider into Toronto semi-finals
-
Rain postponements wreck Montreal Masters schedule
-
Meta pushes global AI vision amid race with OpenAI, Anthropic and China
-
Notts Forest owner Marinakis sues Palace over gun banner - reports
-
US judge ends graft case against India's Adani
-
Koech gets three-year ban, stripped of US 1,500m title
-
Anderson retires after 10 MLB seasons after 'too much pain'
-
Sensational Ingebrigtsen back with more European gold
-
Colombia in state of emergency as quake kills 111
-
'A scare': Brazil player leaps into tunnel in joy over goal
-
Britain's Amy Hunt wins European women's 100m gold
-
USA Swimming CFO Hilliard arrested for alleged theft
-
Trump order pushes for overhaul of childhood vaccine schedule
-
Trump insists Netanyahu relationship 'very good' despite Gaza rift
-
Global stocks mixed while oil prices jump on Hormuz
-
Ingebrigtsen delivers masterclass for seventh European athletics gold
-
Turkey MPs back historic law on reintegrating Kurdish militants
-
Colombia declares state of emergency after quake kills 111
-
'Dreams disappear' as Gaza students await evacuation to Italy
-
Golden relay double for Britain at Europeans as Marchand takes silver
-
Third European gold for Schilder in women's shot put
-
Barcelona's Araujo heads to Liverpool on loan
-
Golden relay double for Britain at Europeans as Marchand settles for silver
-
Tupac Shakur murder trial begins 30 years after rapper's death
-
US had hottest month on record in July
-
Russia bars only anti-war party from elections
-
Colombia quake leaves 69 dead, with more trapped under rubble
-
Boeing to divest tech ventures for stake in air-taxi startup
-
Bookmap Announces Partnership with Plus500 to Expand Futures Trading Access
-
Major quake rocks Colombia and neighbors, 18 confirmed dead
-
Barcelona turn down PSG offer for Torres
-
Brazil aircraft maker Embraer raises outlook after record revenue
-
Buildings collapse as major quake rocks Colombia and neighbors
-
Drought forces water restrictions across nearly 70 percent of France
-
Meta releases new AI model as Zuckerberg lays out vision
-
Europe wary as gas stocks languish at lows while winter looms
US medical agency will scale back testing on monkeys
The United States will scale back certain drug-safety testing requirements on monkeys, federal regulators said Tuesday, marking the latest step by President Donald Trump's administration to limit the use of animals in research.
Under new draft guidance from the Food and Drug Administration, computer models, lab-grown mini-organs, and human studies will replace the use of non-human primates in testing monoclonal antibodies -- lab-engineered proteins used to treat cancers, autoimmune conditions and other diseases.
"We are delivering on our roadmap commitment to eliminate animal testing requirements in drug evaluation and our promise to accelerate cures and meaningful treatments for Americans," FDA Commissioner Marty Makary said in a statement.
The statement added that typical nonclinical programs involving monoclonal antibodies could include more than 100 macaque monkeys -- apes are no longer used in any invasive research in the US -- yet often do not yield human-approved treatments.
The move was welcomed by animal-advocacy groups.
Zaher Nahle, a former animal researcher who is now the senior scientific advisor for nonprofit Center for a Humane Economy, told AFP the move was an "important step."
"These primates are not reliable in terms of predicting the toxicity, so you can get at least equal or better results in terms of your accuracy in predicting toxicology using other approaches," he added.
What's more, he noted, studies show that more than 90 percent of drugs deemed safe and effective in animals fail to win approval for human use.
The FDA's announcement follows a report in the journal Science last month that the Centers for Disease Control and Prevention would close its primate labs.
It "moves us one step closer to wiping out the federal government's wasteful monkey business," Justin Goodman of White Coat Waste Project told AFP.
But the National Institutes of Health -- the country's primary biomedical research agency -- remains a notable "outlier," he added. According to public data, 7,700 primates are confined in federal government labs and breeding facilities, of which 6,700 are at NIH.
Advocates of animal research have pushed back.
"Poorly planned transitions -- including premature study termination -- can place animals at serious risk and may undermine years of scientific investment intended to strengthen public health preparedness and advance lifesaving medical progress," advocacy group Americans for Medical Progress said after the CDC news was reported.
Proponents of animal testing say the research has been indispensable for major medical advances, including vaccines for diphtheria, yellow fever, measles and Covid-19.
Critics counter that decades-old laws have created regulatory lock-in, that publication incentives reward animal studies in top journals, and that a lucrative "animal-industrial complex" has helped entrench the status quo.
O.Gaspar--PC